Abstract:Background: Early identification of patients at risk of developing severe illness and timely interventions to prevent deterioration have the potential to improve outcomes in coronavirus disease 2019 (COVID-19) patients. Herein, we conducted this study to develop and validate a machine learning model for the early prediction of progression risk in COVID-19 patients. Methods: 424 patients with non-severe COVID-19 who underwent chest computed tomography (CT) scan on admission were included in the primary cohort of this retrospective multicentre study. The candidate feature set included 43 baseline clinical variables and CT quantitative measurements determined using deep learning-based segmentation and unsupervised texture clustering. The endpoint was the development of severe COVID-19. The optimal machine learning classifier and feature subset were selected for model construction. The performance of the prediction model was evaluated and tested in an external validation cohort consisting of 98 patients. The performance and clinical usefulness of the model were compared with the CALL score. Findings: There were no significant differences in the clinical characteristics between the primary and validation cohorts, including the prevalence of severe illness (8.7% vs. 8.2%, P = 0.858). The machine learning method extreme gradient boosting (XGBoost) and optimal feature subset including lactic dehydrogenase (LDH), comorbidities, CT lesion ratio (lesion%), and hypersensitive cardiac troponin I (hs-cTnI) were selected for model construction. COVID-19 patients who developed severe illness could be identified by our simplified XGBoost classifier with AUC of 0.956 and accuracy of 0.892 in the primary cohort. The test on the validation cohort showed comparable performance with that of the primary cohort. Compared with the CALL score, the simplified XGBoost classifier showed improved performance (AUC: 0.954 vs. 0.831, P < 0.001) and was clinically useful. Interpretation: A machine learning classifier incorporating LDH, comorbidities, CT lesion%, and hs-cTnI could be conveniently and effectively used as an early predictor of progression risk in patients with COVID-19, opening up the possibility for patient stratification and treatment allocation.Funding Statement: This study was supported by National Natural Science Foundation of China (81771827, 81471715 to Rong).Declaration of Interests: The authors declare no competing financial interests.Ethics Approval Statement: The Institutional Review Board of Third Xiangya Hospital approved our study and waived the informed consent of patients for the retrospective nature of this study.

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Early Warning Biomarkers for COVID-19 Progression and Myocardial Injury

IP-10 and MCP-1 As Biomarkers Predicting Disease Severity of COVID-19

5-hydroxymethylcytosine Epigenetic Markers in COVID-19-Associated Acute Coronary Syndrome: Insights into Neutrophil Activation and PDE4D Upregulation

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA As Diagnostic and Predictive Biomarkers for Coronary Artery Disease

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer’s Disease

5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA As Candidate Diagnostic and Predictive Biomarkers for Coronary Artery Disease

Time-series Plasma Cell-Free DNA Analysis Reveals Disease Severity of COVID-19 Patients

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA As Diagnostic Biomarkers for Late-Onset Alzheimer's Disease

Transcriptional Start Site Coverage Analysis in Plasma Cell-Free DNA Reveals Disease Severity and Tissue Specificity of COVID-19 Patients

A 5-Hydroxymethylcytosine-based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: the METHOD-2 Study

Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease

Implications of cardiac markers in risk-stratification and management for COVID-19 patients

Abstract 4135025: Inflammation-related 5-Hydroxymethylation Signatures As Markers for Clinical Presentations of Coronary Artery Disease

Plasma Cell-Free DNA Promise Monitoring and Tissue Injury Assessment of COVID-19

Early Prediction of Mortality Risk among Patients with Severe COVID-19, Using Machine Learning

Machine Learning Based on Clinical Variables and Chest CT Quantitative Measurements for Early Prediction of Progression Risk in COVID-19 Patients: A Multicentre Study

Early Detection of Non-Small Cell Lung Cancer with Novel 5-Hydroxymethylcytosine DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma

Fragmentomics of plasma mitochondrial and nuclear DNA inform prognosis in COVID-19 patients with critical symptoms

Risk factors for myocardial injury in patients with coronavirus disease 2019 in China.

Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery

Myoglobin and C-reactive protein are efficient and reliable early predictors of COVID-19 associated mortality